PMID- 34966484
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211231
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 12
IP  - 26
DP  - 2021 Dec 21
TI  - Using drug scheduling to manage adverse events associated with hedgehog pathway 
      inhibitors for basal cell carcinoma.
PG  - 2531-2540
LID - 10.18632/oncotarget.28145 [doi]
AB  - Basal cell carcinoma (BCC) is the most common malignancy and form of skin cancer 
      worldwide; advanced BCC, either as locally advanced BCC (laBCC) or metastatic BCC 
      (mBCC), can cause substantial tissue invasion and morbidity. Until the recent 
      availability of the hedgehog pathway inhibitors (HHIs) sonidegib and vismodegib, 
      treatment options for advanced BCC were limited. These agents demonstrate 
      efficacy in patients with laBCC and mBCC; however, the adverse events (AEs) 
      associated with these agents can lead to treatment interruption or 
      discontinuation and reduced quality of life, all of which significantly impact 
      long-term adherence to therapy, which might affect clinical outcome. Given that 
      most AEs are class-related effects, switching HHIs does not appear to lead to a 
      significantly different AE profile, underscoring the importance of maintaining 
      patients on their first HHI. Interrupting treatment of sonidegib and vismodegib 
      does not appear to undermine the efficacy of these agents and is therefore a 
      practical option to manage AEs in order to maintain continued treatment and 
      disease control.
CI  - Copyright: (c) 2021 Lear et al.
FAU - Lear, John T
AU  - Lear JT
AD  - Manchester Academic Health Science Centre, University of Manchester, Manchester, 
      UK.
FAU - Dummer, Reinhard
AU  - Dummer R
AD  - Department of Dermatology, University Hospital, University of Zurich, Zurich, 
      Switzerland.
AD  - Skin Cancer Center, University Hospital, University of Zurich, Zurich, 
      Switzerland.
FAU - Guminski, Alexander
AU  - Guminski A
AD  - Department of Medical Oncology, Royal North Shore Hospital, St Leonards, 
      Australia.
AD  - Faculty of Medicine, Sydney Medical School, The University of Sydney, Sydney, 
      Australia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211221
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
PMC - PMC8711575
OTO - NOTNLM
OT  - adverse events
OT  - basal cell carcinoma
OT  - drug scheduling
OT  - hedgehog inhibitor
OT  - sonidegib
COIS- CONFLICTS OF INTEREST JTL receives personal fees from Novartis and Sun 
      Pharmaceutical Industries, Inc. RD has participated in advisory boards and 
      consulted for Amgen; Bristol-Myers Squibb; Catalym; Merck Sharpe & Dohme; 
      Novartis Pharmaceutical Corporation; Pierre Fabre; Roche; Sanofi; Second Genome; 
      Sun Pharmaceutical Industries, Inc.; and Takeda. AG has participated in advisory 
      boards for Bristol-Myers Squibb, Pfizer, and Sanofi; received honoraria from 
      Novartis; and received travel support from Astellas; Bristol-Myers Squibb; and 
      Sun Pharmaceutical Industries, Inc.
EDAT- 2021/12/31 06:00
MHDA- 2021/12/31 06:01
PMCR- 2021/12/21
CRDT- 2021/12/30 05:39
PHST- 2021/10/08 00:00 [received]
PHST- 2021/11/10 00:00 [accepted]
PHST- 2021/12/30 05:39 [entrez]
PHST- 2021/12/31 06:00 [pubmed]
PHST- 2021/12/31 06:01 [medline]
PHST- 2021/12/21 00:00 [pmc-release]
AID - 28145 [pii]
AID - 10.18632/oncotarget.28145 [doi]
PST - epublish
SO  - Oncotarget. 2021 Dec 21;12(26):2531-2540. doi: 10.18632/oncotarget.28145. 
      eCollection 2021 Dec 21.